openPR Logo
Press release

Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis

02-27-2012 09:32 AM CET | Science & Education

Press release from: Nanion Technologies

Nanion acquires the well-established SURFE2R technology, allowing state-of-the-art measurements of transporter protein activity and function. The SURFE2R technology is an excellent enhancement to Nanion’s existing products which until now covered ion channels and nanopores.

Nanion Technologies is one of the leading providers of high quality automated patch clamp systems. Nanion’s efficient and versatile products drastically improve the data output in patch clamp-based ion channel screening, safety testing and scientific research. Since 2003, Nanion has launched three automated patch clamp platforms, the Port-a-Patch (2003), the Patchliner (2006), the SyncroPatch 96 (2010), and recently introduced the Orbit 16 – a device for parallel bilayer recordings. Existing products target ion channels and nanopores in cell- and cell-free membranes for highly detailed information about kinetics, function, and compound pharmacology.

Dr. Niels Fertig, CEO of Nanion Technologies, says:
“By acquiring the SURFE2R technology developed by IonGate / Scientific Devices Heidelberg, Nanion enters yet another market segment. It is an excellent addition to our product portfolio and a unique platform since it allows direct measurements of transporter activity and function. Further on, the platform has been validated with a wide variety of membrane preparations ranging from bacteria to native cells and cell lines. With this acquisition, Nanion becomes a one-stop-shop for functional membrane protein analysis, extending its product portfolio from screening instrumentation for ion channels and nanopores to now also include transporter proteins. “

The SURFE2R product line will be launched during the second half of 2012.

About Nanion Nanion Technologies:
Nanion Technologies GmbH is a German Private Limited Company and was
founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion’s team has developed and globally established two highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.
Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the technique of patch clamping. Nanion was nominated in 2007 for Germany's most prestigious innovation award the Deutscher Zukunftspreis (German Future Prize, Federal President's Award for Technology and Innovation).

Nanion Technologies
Gabrielenstrasse 9
80636 Munich

Press contact: Dr. Cecilia Farre, Marketing Director,

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Nanion Acquires the SURFE2R Technology for Transporter Protein Analysis here

News-ID: 212357 • Views: 1415

More Releases from Nanion Technologies

Nanion Starts Shipping the SyncroPatch 384 Patch Engine - a Revolutionary Instru …
The brand-new SyncroPatch 384 Patch Engine (PE) now released by Nanion Technologies propels ion channel drug discovery to a new level. Designed for seamless integration into process-automated drug screening environments, the Patch Engine is equipped with 384 patch clamp amplifiers and an advanced 384 channel liquid handling robot. The SyncroPatch 384PE is the high quality, automated patch clamp system able to finally thrust gold standard electrophysiology from secondary to primary
Nanion Introduces New Product Family: CardioExcyte 96 for Cardiac Toxicity Profi …
Munich, Germany, September 12, 2013; The CardioExcyte 96 is a high resolution device recording contractility in intact cardiomyocyte networks utilizing non-invasive impedance measurements. The system allows cost-efficient, early compound safety profiling using stem cell-derived cardiomyocytes, freshly dissociated cardiomyocytes or beating 3D-cell clusters. Cardiac safety assessment is a vital part of drug development since late withdrawals of compound candidates, due to heart liability issues such as ventricular arrhythmia, are very
Nanion Introduces NPC-Certified Cell Lines
Munich, Germany, November 08, 2012; Nanion’s automated patch clamp platforms are known for their high cell compatibility, even for primary cells and stem cells. Nanion now introduces “Nanion Approved Cells”, where commercially available cell lines from several providers have been evaluated and certified based on cell and platform performance. The approved cells can be directly purchased through Nanion, so that Nanion’s customers get a complete package of APC platform and
Nanion Introduces the Orbit 16 – a Pioneering Device for Parallel Lipid Bilaye …
Munich, Germany, February 23, 2012; Today, Nanion announces the introduction of a completely new product line for efficient analysis of bilayer-reconstituted ion channels and nanopores. The first of these, the Orbit 16, allows for automated formation of, and recordings from 16 bilayers in parallel, combining efficient data generation and ultra-high data quality. The Orbit 16 takes the pain out of bilayer recordings and facilitates efficient data generation through 16

All 5 Releases

More Releases for SURFE2R

IonGate honored for its SURFE2R Technology as “Landmark in the Land of Ideas 2 …
Frankfurt/Main (Germany), November 18, 2008. IonGate Biosciences GmbH celebrated its election as “Landmark in the Land of Ideas“ by the initiative “Germany – Land of Ideas”. IonGate’s patented SURFE2R Technology (SURFace Electrogenic Event Reader) won the jury’s acclaim in the nationwide contest “365 Landmarks in the Land of Ideas”. SURFE2R Technology enables scientists to detect extremely small electric currents in cell membranes. Thus, it becomes possible to analyze the otherwise
IonGate increases throughput for transporter-based drug discovery with new SURFE …
Frankfurt/Main (Germany), 28th July 2008. IonGate Biosciences GmbH is pleased to announce the market launch of the innovative SURFE2R Workstation 5000. This fully integrated screening center is the new flagship model of IonGate’s SURFE2R product family, paving new ways in industrial automation of transporter screening for the pharmaceutical industry. With SURFE2R Workstation 5000, IonGate presents the latest automated system for direct functional measurement of the important new target class of transport
IonGate hosts workshop and presents new SURFE2R prototype at SBS 2008
Frankfurt/Main (Germany), March 31, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins in a workshop at the SBS 2008, 14th Annual Conference & Exhibition of the Society of Biomolecular Sciences. The meeting takes place in St. Louis, Missouri, USA, on April 6 – 10, 2008. Additionally IonGate will give an exclusive preview of the prototype for the new SURFE2R Workstation 5000. Immediately
IonGate starts commercialization of SURFE2R in Asia
Frankfurt/Main, Germany, March 12, 2008. IonGate Biosciences is expanding its operations to market the SURFE2R (SURFace Electrogenic Event Reader) Technology to the Japanese market. BRC - Bio Research Center Co. Ltd Nagoya, Japan and IonGate jointly introduce the proprietary technique to automatically screen transport proteins in high throughput at meetings in Japan, thus making the technology accessible to the Asian market. BRC is an established partner able to supply Japan’s researchers
IonGate presents SURFE2R Technology and relevant fields of application at Biophy …
Frankfurt/Main (Germany), January 28, 2008. IonGate Biosciences GmbH will present its SURFE2R Technology for label-free and automatic measurement of transport proteins at the 52nd Annual Meeting and 16th International Biophysics Congress. The joint meeting of the American Biophysical Society takes place in Long Beach, California, USA, on February 2 – 6, 2008. Scientists from industry, universities and private academic institutes use this opportunity to present results of their latest research
IonGate sells SURFE2R Technology for the first time overseas
Frankfurt/Main (Germany), 2nd November, 2007. IonGate Biosciences GmbH announces an excellent start into the worldwide marketing of its SURFE2R Technology. Already established in Europe, it has now entered the North American market. In September the Department of Biochemistry and Molecular Biology at the University of Calgary, in Canada, purchased a SURFE2R One for research on transport proteins. In just a few weeks Prof. Jonathan Lytton, Professor in the Department and